ArticleThe Journal of clinical investigation2004
Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Trial
- Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release.Molecular therapy. Advances · 2026Article
- APC-targeted DNA vaccines: the role of CCL19 in immune cell recruitment and early onset of the immune response.Cancer immunology, immunotherapy : CII · 2026Article
- Role of mucosal chemokines in the development of tissue-resident CD4Frontiers in immunology · 2026Review
- Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy.Cells · 2025Review
- Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity.Gene therapy · 2025Article
- Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations.Frontiers in immunology · 2025Review
- Review
- In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy.The Journal of clinical investigation · 2024Article
- Flt3L and GM-CSF enhance anti-tumor effect of HPV16/18 vaccine via increasing immune response.American journal of translational research · 2020Article
- Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.Frontiers in immunology · 2020Article
- Review
- Article
- Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3- Dioxygenase Mediated-antitumor Efficiency.Molecular therapy. Nucleic acids · 2016Article
- Toll-Like Receptor 9 Activation Rescues Impaired Antibody Response in Needle-free Intradermal DNA Vaccination.Scientific reports · 2016Article
- Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency.Investigational new drugs · 2015Article
- CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.Journal of virology · 2014Article
- Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Pharmaceutics · 2014Article
- DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.Clinical and experimental vaccine research · 2013Article
- Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Cancer gene therapy · 2013Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
DCs are critical for priming adaptive immune responses to foreign antigens. However, the utility of harnessing these cells in vivo to optimize the immunogenicity of vaccines has not been fully explored. Here we investigate a novel vaccine approach that involves delivering synergistic signals that both recruit and expand DC populations at the site of antigen production. Intramuscular injection of an unadjuvanted HIV-1 envelope (env) DNA vaccine recruited few DCs to the injection site and elicited low-frequency, env-specific immune responses in mice. Coadministration of plasmids encoding the chemokine macrophage inflammatory protein-1alpha (MIP-1alpha) and the DC-specific growth factor fms-like tyrosine kinase 3 ligand with the DNA vaccine resulted in the recruitment, expansion, and activation of large numbers of DCs at the site of inoculation. Consistent with these findings, coadministration of these plasmid cytokines also markedly augmented DNA vaccine---elicited cellular and humoral immune responses and increased protective efficacy against challenge with recombinant vaccinia virus. These data suggest that the availability of mature DCs at the site of inoculation is a critical rate-limiting factor for DNA vaccine immunogenicity. Synergistic recruitment and expansion of DCs in vivo may prove a practical strategy for overcoming this limitation and potentiating immune responses to vaccines as well as other immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.